Posted by Michael Wonder on 07 Jan 2026
Milestone Pharmaceuticals announces acceptance of marketing authorisation application for etripamil nasal spray in PSVT by the EMA
6 January 2026 - Milestone Pharmaceuticals today announced the acceptance of a marketing authorisation application by the EMA seeking the approval of etripamil nasal spray, developed to be the first rapid, reliable option in the treatment of paroxysmal supraventricular tachycardia outside of the healthcare setting.
A decision on approval is expected by the first quarter of 2027.
